Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-25-100723
Filing Date
2025-04-28
Accepted
2025-04-28 16:46:29
Documents
22
Period of Report
2025-06-04

Document Format Files

Seq Description Document Type Size
1 PRE 14A d904380dpre14a.htm   iXBRL PRE 14A 761281
6 GRAPHIC g904380dsp013.jpg GRAPHIC 173399
7 GRAPHIC g904380dsp014.jpg GRAPHIC 125742
8 GRAPHIC g904380g23b81.jpg GRAPHIC 63081
9 GRAPHIC g904380g37o81.jpg GRAPHIC 60671
10 GRAPHIC g904380g41z56.jpg GRAPHIC 169376
11 GRAPHIC g904380g81d74.jpg GRAPHIC 152379
  Complete submission text file 0001193125-25-100723.txt   3353176

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nams-20241231.xsd EX-101.SCH 3314
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nams-20241231_def.xml EX-101.DEF 2263
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nams-20241231_lab.xml EX-101.LAB 2257
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nams-20241231_pre.xml EX-101.PRE 1300
24 EXTRACTED XBRL INSTANCE DOCUMENT d904380dpre14a_htm.xml XML 183250
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-41562 | Film No.: 25881202
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)